{"id":"NCT00527072","sponsor":"Centocor Ortho Biotech Services, L.L.C.","briefTitle":"PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept","officialTitle":"A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab (REMICADE�) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL�)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2009-05","completion":"2009-10","firstPosted":"2007-09-10","resultsPosted":"2010-06-24","lastUpdate":"2012-09-03"},"enrollment":217,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"infliximab","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months, without enough improvement in their psoriasis symptoms.","primaryOutcome":{"measure":"Number of Patients Who Achieve a Physician Global Assessment (PGA) Score of Minimal (1) or Clear (0)","timeFrame":"Week 10","effectByArm":[{"arm":"Infliximab","deltaMin":138,"sd":null}],"pValues":[{"comp":"OG000","p":"0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22153792"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":215},"commonTop":["Upper respiratory tract infection","Arthralgia","Headache","Nasopharyngitis","Cough"]}}